The FDA has awarded Lipogems an investigational device exemption for a clinical trial on the company’s microfragmented fat system for treatment of knee osteoarthritis compared with corticosteroids, according to a press release.
The Lipogems microfragmented fat (MFat) system has been used to process adipose tissue for general applications in orthopedics, arthroscopy and nine specialties in more than 50,000 procedures under its current FDA 510(k) clearance and CE mark and is anticipated for approval in the setting of knee OA, according to the release.
“We are excited to achieve this